The anti-diabetic drug metformin inhibits vascular endothelial growth factor expression via the mammalian target of rapamycin complex 1/hypoxia-inducible factor-1α signaling pathway in ELT-3 cells

Molecular and Cellular Endocrinology

Volumn 399, Issue , 2015, Pages 1-8

  Tadakawa, Mari ^a   Takeda, Takashi ^a,b   Li, Bin ^a   Tsuiji, Kenji ^a   Yaegashi, Nobuo ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Angiogenesis; HIF 1 ; Metformin; MTOR; Uterine leiomyoma; VEGF

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MESSENGER RNA; METFORMIN; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; ANTIDIABETIC AGENT; HIF1A PROTEIN, RAT; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; TARGET OF RAPAMYCIN KINASE; TUMOR PROTEIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A, RAT; VASCULOTROPIN A;

ANIMAL CELL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL HYPOXIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; ELT 3 CELL LINE; FEMALE; GENE EXPRESSION; IN VITRO STUDY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN SYNTHESIS INHIBITION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SUPERNATANT; TUMOR CELL LINE; UTERUS MYOMA; ANIMAL; BIOSYNTHESIS; DRUG EFFECTS; GENE EXPRESSION REGULATION; LEIOMYOMA; METABOLISM; PATHOLOGY;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HYPOGLYCEMIC AGENTS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LEIOMYOMA; METFORMIN; MULTIPROTEIN COMPLEXES; NEOPLASM PROTEINS; RATS; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84908592491     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2014.08.012     Document Type: Article

References (44)

1. Bailey C.J., Path M.R., Turner R.C. Metformin. N. Eng. J. Med 1996, 334:574-579.
2. Berra E., Benizri E., Ginouves A., Volmat V., Roux D., et al. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1α in normoxia. EMBO J. 2003, 22:4082-4090.
3. Crabtree J.S., Jelinsky S.A., Harris H.A., Choe S.E., Cotreau M.M., et al. Comparison of human and rat uterine leiomyomata: identification of a dysregulated mammalian target of rapamycin pathway. Cancer Res 2009, 69:6171-6178.
4. Di Lieto A., De Falco M., Pollio F., Mansueto G., Salvatore G., et al. Clinical response, vascular change, and angiogenesis in gonadotropin-releasing hormone analogue-treated women with uterine myomas. J. Soc. Gynecol. Investig 2005, 12:123-128.
5. Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist 2004, 9:2-10.
6. Fleischer R., Weston G.C., Vollenhoven B.J., Rogers P.A. Pathophysiology of fibroid disease: angiogensis and regulation of smooth muscle proliferation. Best Pract. Res. Clin. Obstet. Gynaecol 2008, 22:603-614.
7. Forsythe J.A., Jiang B.H., Iyer N.V., Agani F., Leung S.W., et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol 1996, 16:4604-4613.
8. Garcia-Maceira P., Mateo J. Silibinin inhibits hypoxia-inducible factor-1α and mTOR/p70S6K/4E-BP1 signaling pathway in human cervical and hepatoma cancer cells: implications for anticancer therapy. Oncogene 2009, 28:313-324.
9. Gentry C.C., Okolo S.O., Fong L.F., Crow J.C., Maclean A.B., et al. Quantification of vascular endothelial growth factor-A in leiomyomas and adjacent myometrium. Clin. Sci. (Lond.) 2001, 101:691-695.
10. Gwinn D.M., Shackelford D.B., Egan D.F., Mihaylova M.M., Mery A., et al. AMPK phospholylation of raptor mediates a metabolic checkpoint. Mol. Cell 2008, 30:214-226.
11. Hague S., Zhang L., Oehler M.K., Manek S., MacKenzie I.Z., et al. Expression of the hypoxically regulated angiogenic factor adrenomedullin correlates with uterine leiyomyoma vascular density. Clin. Cancer Res 2000, 6:2808-2814.
12. Hara K., Maruki Y., Long X., Yoshino K., Oshiro N., et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 2002, 110:177-189.
13. Hassan M.H., Eyzaquirre E., Arafa H.M., Hamada F.M., Salama S.A., et al. Memy I: a novel murine model for uterine leiomyoma using adenovirus-enhanced human fibroid explants in severe combined immune deficiency mice. Am. J. Obstet. Gynecol 2008, 199:156. e1-8.
14. Hou P., Zhao L., Li Y., Luo F., Wang S., et al. Comparative expression of thioredoxin-1 in uterine leiomyomas and myometrium. Mol. Hum. Reprod 2013, 20:148-154.
15. Howe S.R., Gottardis M.M., Everitt J.I., Goldsworthy T.L., Wolf D.C., et al. Rodent model of reproductive tract leiomyomata. Establishment and characterization of tumor-derived cell lines. Am. J. Pathol 1995, 16:1568-1579.
16. Howe S.R., Gottardis M.M., Everitt J.I., Walker C.L. Estrogen stimulation and tamoxifen inhibition of leiomoyma cell growth in vitro and in vivo. Endocrinology 1995, 136:4996-5003.
17. Huang R., Lin Y., Shi Q., Flowers L., Ramachandran S., et al. Enhanced protein profiling arrays with ELISA-based amplification for high-throughput molecular changes of tumor patient's plasma. Clin. Cancer Res 2004, 10:598-609.
18. Karar J., Maity A. PI3K/AKT/mTOR pathway in angiogenesis. Front. Mol. Neurosci 2011, 4:1-8.
19. Kolankaya A., Arici A. Myomas and assisted reproductive technologies: when and how to act?. Obstet. Gynecol. Clin. North Am 2006, 33:145-152.
20. Laughner E., Taghavi P., Chiles K., Mahon P.C., Semenza G.L. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1 alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol. Cell. Biol 2001, 21:3995-4004.
21. Levy G., Hill M.J., Beall S., Zarek S.M., Segars J.H., et al. Leiomyoma: genetics, assisted reproduction, pregnancy and therapeutic advances. J. Assist. Reprod. Genet 2012, 29:703-712.
22. Li B., Takeda T., Tsuiji K., Kondo A., Kitamura M., et al. The antidiabetic drug metformin inhibits uterine leiomyoma cell proliferation via an AMP-activated protein kinase signaling pathway. Gynecol. Endocrinol 2013, 29:87-90.
23. Libby G., Donnelly L.A., Donnan P.T., Alessi D.R., Morris A.D., et al. New users of metformin are at low risk of incident cancer. Diabetes Care 2009, 32:1620-1625.
24. Mayer A., Hockel M., Wree A., Leo C., Horn L.C., et al. Lack of hypoxic response in uterine leiomyomas despite severe tissue hypoxia. Cancer Res 2008, 68:4719-4726.
25. McCarty M.F. mTORC1 activity as a determinant of cancer risk - rationalizing the cancer-preventive effects of adiponectin, metformin, rapamycin, and low-protein vegan diets. Med. Hypotheses 2011, 77:642-648.
26. Okolo S. Incidence, aetiology and epidemiology of uterine fibroids. Best Pract. Res. Clin. Obstet. Gynaecol 2008, 22:571-588.
27. O'Reilly K.E., Rojo F., She Q., Solit D., Mills G.B., et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates AKT. Cancer Res 2006, 66:1500-1508.
28. Rattan R., Graham R.P., Maguire J.L., Giri S., Shridhar V. Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxity in vivo. Neoplasia 2011, 13:483-491.
29. Sahra I.B., Marchand-Brustel Y.L., Tanti J.F., Bost F. Metformin in cancer therapy: a new perspective for an old antidiabetic drug?. Mol. Cancer Ther 2010, 9:1092-1099.
30. Shofield C.J., Ratcliffe P.J. Oxygen sensing by HIF hydroxylases. Nat. Rev. Mol. Cell Biol 2004, 5:343-354.
31. Skinner H.D., Zheng J.Z., Fang J., Agani F., Jiang B.H. Vascular endothelial growth factor transcriptional activation is mediated by hypoxia-inducible factor 1α, HDM2, and p70S6K1 in response to phosphatidylinositol 3-kinase/AKT signaling. J. Biol. Chem 2004, 279:45643-45651.
32. Slomiany M.G., Rosenzweig S.A. Hypoxia-inducible factor-1-dependent and -independent regulation of insulin-like growth factor-1-stimulated vascular endothelial growth factor secretion. J. Pharm. Exp. Ther 2006, 318:666-675.
33. Tal R., Segars J.H. The role of angiogenic factors in fibroid pathogenesis: potential implications for future therapy. Hum. Reprod. Update 2014, 20:194-216.
34. Tan B.K., Adya R., Chen J., Farhatullah S., Heutling D., et al. Metformin decreases angiogenesis via NF-κB and Erk1/2/Erk5 pathways by increasing the antiangiogenic thrombospondin-1. Cardiovasc. Res 2009, 83:566-574.
35. Tsuiji K., Takeda T., Li B., Kondo A., Ito M., et al. Establishment of a novel xenograft model for human uterine leiomyoma in immunodeficient mice. Tohoku J. Exp. Med 2010, 222:55-61.
36. Varghese B.V., Koohestani F., McWilliams M., Colvin A., Gunewardena S., et al. Loss of repressor REST in uterine fibroids promotes aberrant G protein-coupled receptor 10 expression and activates mammalian target of rapamycin pathway. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:2187-2192.
37. Walker C.L., Stewart E.A. Uterine fibroids: the elephant in the room. Science 2005, 308:1589-1592.
38. Walker C.L., Hunter D., Everitt J.I. Uterine leiomyoma in Eker rat: a unique model for important diseases of women. Genes Chromosomes Cancer 2003, 38:349-356.
39. Wei J.J., Zhang X.M., Chiriboga L., Yee H., Perle M.A., et al. Spatial differences in biologic activity of large uterine leiomyomata. Fertil. Steril 2006, 85:179-187.
40. Wullschleger S., Loewith R., Hall M.N. TOR signaling in growth and metabolism. Cell 2006, 124:471-484.
41. Xavier D.O., Amaral L.S., Gomes M.A., Rocha M.A., Campos P.R., et al. Metformin inhibits inflammatory angiogenesis in a murine sponge model. Biomed. Pharmacother 2010, 64:220-225.
42. Xu Q., Ohara N., Chen W., Liu J., Sasaki H., et al. Progesterone receptor modulator CDB-2914 downregulates vascular endothelial growth factor, adrenomedullin and their receptors and modulates progesterone receptor content in cultured human uterine leiomyoma cells. Hum. Reprod 2006, 21:2408-2416.
43. Yuan Y., Hilliard G., Ferguson T., Millhorn D.E. Cobalt inhibits the interaction between hypoxia-inducible factor-α and von Hippel-Lindau protein by the direct binding to hypoxia-inducible factor-α. J. Biol. Chem 2003, 278:15911-15916.
44. Zakikhani M., Dowling R., Fantus I.G., Sonenberg N., Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for the breast cancer cells. Cancer Res 2006, 66:10269-10273.